<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36324">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633683</url>
  </required_header>
  <id_info>
    <org_study_id>XP110</org_study_id>
    <nct_id>NCT02633683</nct_id>
  </id_info>
  <brief_title>An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS</brief_title>
  <acronym>RLS</acronym>
  <official_title>A Multicenter Open-Label Extension Study to Evaluate the Efficacy and Safety of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets in Adolescents Aged 13 to 17 Years Old With Moderate-to-Severe Primary Restless Legs Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XenoPort, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>XenoPort, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the trial are to evaluate the long-term efficacy and safety of HORIZANT
      (Gabapentin Enacarbil) 600 mg daily, for the treatment of RLS in adolescents (13 to 17 years
      of age) diagnosed with moderate-to-severe primary RLS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impression of Improvement (CGI-I) score at Week 12.</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impression of Improvement (CGI-I) score at Week 24.</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impression of Improvement (CGI-I) score at Week 36.</measure>
    <time_frame>Week 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportions of patients with AEs, fatal serious adverse events (SAEs), non-fatal SAEs, discontinuations due to AEs at all post-dose time points; and proportion of patients with neuropsychiatric AEs.</measure>
    <time_frame>Week 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change on the IRLS rating scale from baseline to Weeks 12, 24, and 36. Baseline will be carried forward from XP108/XP109 data into XP110.</measure>
    <time_frame>baseline to Weeks 12, 24, and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who are responders, assessed on the CGI-I scale as &quot;much improved&quot; or &quot;very much improved&quot; (CGI-I rating of 1 or 2, respectively) at Weeks 12, 24, and 36.</measure>
    <time_frame>Weeks 12, 24, and 36</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>RLS</condition>
  <arm_group>
    <arm_group_label>HORIZANT 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HORIZANT 600 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HORIZANT 600 mg</intervention_name>
    <description>HORIZANT 600 mg once daily</description>
    <arm_group_label>HORIZANT 600 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who completed participation in 1 of the 2 preceding studies with HORIZANT, Study
        XP108 or Study XP109.

          -  Negative pregnancy test for females of childbearing potential. Male patients able to
             father a child must agree to use a barrier method (male condom, female condom,
             diaphragm, or cervical cap) with spermicide for at least 30 days prior to dosing and
             throughout the study. Fertile, sexually active patients must agree to use 2 medically
             accepted methods of contraception

          -  Patients must be willing to refrain from using any drugs that are likely to affect
             RLS or sleep assessments for the duration of the study.

          -  Signed patient and parent (or legal guardian) Institutional Review Board
             (IRB)-approved assent and consent forms before any study procedures are carried out

        Exclusion Criteria:

          -  Patients who, in the opinion of the investigator, would be noncompliant with the
             study visit schedule, procedures, or medication administration

          -  Patients who have developed clinically significant or unstable medical conditions, or
             who would otherwise be unsuitable for participation in a continuation study with
             gabapentin enacarbil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Camilla Alexander</last_name>
    <phone>520-252-1908</phone>
    <email>Camilla.Alexander@wwctrials.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xenoport Investigational Site</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xenoport Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xenoport Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xenoport Investigational Site</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xenoport Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xenoport Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xenoport Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>March 2, 2016</lastchanged_date>
  <firstreceived_date>December 10, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Restless Legs Syndrome</keyword>
  <keyword>RLS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Restless Legs Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
